CYTK Cytokinetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CYTK

Price (delayed)

$73.45

Market cap

$10.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.22

Enterprise value

$11.23B

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 19

Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is ...

Highlights
CYTK's equity has surged by 79% since the previous quarter and by 53% year-on-year
Cytokinetics's quick ratio has soared by 58% from the previous quarter
The debt has increased by 48% YoY
The net income is down by 47% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cytokinetics.com
Peers: ORKA LGND ARRY AMGN

Key stats

What are the main financial stats of CYTK

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
-2.9%
1 week
-9.73%
1 month
-10.69%
1 year
99.16%
YTD
15.6%
QTD
-13.78%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$67.67M
Gross profit
$59.53M
Operating income
-$707.91M
Net income
-$894M
Gross margin
88%
Net margin
-1,321.1%
The net margin has plunged by 87% YoY and by 69% from the previous quarter
Cytokinetics's operating margin has plunged by 73% from the previous quarter and by 64% YoY
The net income is down by 47% year-on-year and by 8% since the previous quarter
Cytokinetics's gross profit has decreased by 41% from the previous quarter and by 27% YoY

Price vs fundamentals

How does CYTK's price correlate with its fundamentals

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
143.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
165.9
The EPS has contracted by 42% YoY and by 6% from the previous quarter
CYTK's equity has surged by 79% since the previous quarter and by 53% year-on-year
CYTK's P/S is 67% below its 5-year quarterly average of 440.8 but 42% above its last 4 quarters average of 101.3
The revenue has declined by 36% since the previous quarter and by 21% year-on-year

Efficiency

How efficient is Cytokinetics business performance
The ROS has plunged by 87% YoY and by 69% from the previous quarter
The company's return on assets fell by 30% YoY but it rose by 4.7% QoQ
CYTK's return on invested capital is down by 18% year-on-year

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 8% smaller than the total liabilities
The company's current ratio has surged by 58% QoQ
Cytokinetics's quick ratio has soared by 58% from the previous quarter
CYTK's equity has surged by 79% since the previous quarter and by 53% year-on-year
The debt has increased by 48% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.